The optimal timing of percutaneous coronary intervention (PCI) in patients undergoing transcatheter aortic valve replacement (TAVR) remains uncertain, with particular concern about renal complications after contrast exposure. This systematic review and meta-analysis evaluated whether staged PCI (performed separately from TAVR) versus concomitant PCI (performed during the same procedural episode as TAVR) alters the incidence of contrast-induced acute kidney injury (CI-AKI).
The authors performed a comprehensive search of MEDLINE, Embase, and Cochrane databases to identify studies that compared staged versus concomitant PCI in patients with aortic stenosis and concomitant coronary artery disease undergoing TAVR. Details on individual study selection criteria, inclusion/exclusion rules, and study-level characteristics were reported in the original preprint; the summary reports pooled data from the identified studies.
A random-effects meta-analytic model was used to pool results across studies. The primary outcome evaluated was the incidence of CI-AKI, expressed as odds ratios (OR) with 95% confidence intervals (CI). The authors also performed subgroup analyses by CI-AKI stage (stage 1, stage 2, and combined stage 3/4) to explore severity-specific effects of PCI timing. Statistical significance was reported using p values for each pooled comparison.
The meta-analysis included 11 studies comprising a total of 7,119 patients. The preprint notes that all source data were drawn from publicly available published reports in cardiovascular journals. The authors declared no competing interests and stated that ethical approvals and participant consents were addressed by the original studies.
When all included studies were pooled, there was no statistically significant difference in the incidence of CI-AKI between staged and concomitant PCI strategies (OR 1.02; 95% CI 0.53 to 1.98; p = 0.959). This indicates no clear overall advantage of staging PCI versus performing PCI concomitantly with TAVR for the composite incidence of CI-AKI across the aggregated datasets.
The authors conducted subgroup analyses by CI-AKI stage. For stage 1 CI-AKI, pooled results showed no significant difference between staged and concomitant PCI (OR 1.99; 95% CI 0.38 to 10.47; p = 0.417). For stage 2 CI-AKI, there was likewise no significant difference (OR 1.01; 95% CI 0.39 to 2.64; p = 0.978). Both subgroup analyses failed to demonstrate a consistent benefit for either timing approach for milder to moderate CI-AKI.
A statistically significant finding emerged for severe kidney injury. Pooled data for combined stage 3/4 CI-AKI favored the staged PCI approach (OR 0.48; 95% CI 0.24 to 0.99; p = 0.046). This suggests that staging PCI apart from TAVR may be associated with a lower odds of the most severe categories of contrast-associated renal injury in the aggregated studies.
The meta-analysis indicates that, across available observational and published data, staging PCI does not consistently reduce the overall incidence of CI-AKI compared with performing PCI concomitantly with TAVR. However, the observed reduction in combined stage 3/4 CI-AKI suggests a potential protective effect of staging for more severe renal injury. Clinicians should interpret this signal cautiously given the nature of the underlying studies and between-study heterogeneity.
The authors report heterogeneity among included studies and emphasize that evidence is not definitive. The analysis pooled data from published studies rather than randomized controlled trials, and important variables that could affect kidney injury risk (for example, baseline renal function, contrast volume, hydration protocols, timing intervals between procedures, and procedural complexity) may not have been consistently reported or adjusted for across studies. The preprint conclusion underscores the need for large-scale randomized controlled trials to clarify whether PCI timing causally influences renal outcomes in patients undergoing TAVR.
This article is a preprint posted on medRxiv and has not undergone peer review; the authors note it should not be used to guide clinical practice until validated. The authors declared no competing interests and stated that all meta-analysis source data were from publicly available published reports. They confirm adherence to ethical reporting standards for the original studies included in the analysis.
Across 11 studies and 7,119 patients, staged PCI did not change the overall pooled risk of CI-AKI compared with concomitant PCI during TAVR, but staged PCI was associated with lower odds of severe (stage 3/4) CI-AKI. Due to heterogeneity and observational data sources, randomized trials are required to determine whether procedural timing should guide strategies to reduce renal injury in the TAVR population.